Regulatory outlook for nanocellulose excipients under FDA’s 2026 nanomaterial framework

Which regulatory pathways are available for nanocellulose excipients in the United States?

Nanocellulose can be introduced via three principal routes:

1. Generally Recognised as Safe (GRAS) notification – If the nanocellulose is intended for oral dosage forms and the manufacturer can demonstrate a history of safe use, a GRAS notice may be filed. The FDA expects a comprehensive safety dossier, including exposure estimates based on the intended dose and the nanocellulose’s physicochemical profile.
2. New Drug Application (NDA) or Abbreviated NDA (ANDA) – For novel formulations, the nanocellulose data become part of the CMC section. The agency will evaluate the excipient alongside the active pharmaceutical ingredient (API) for any impact on bioavailability, stability, or immunogenicity.
3. Investigational New Drug (IND) application – Early‑stage products typically submit an IND. The nanocellulose data are reviewed during the Phase I safety assessment, and any deficiencies must be addressed before progressing to later phases.

The choice of pathway depends on the product’s novelty, the intended route of administration, and the existing safety record of the specific nanocellulose grade. For parenteral or inhalation products, the FDA is more likely to require a full toxicology package, regardless of GRAS status.

What data requirements does the FDA expect for nanocellulose excipients?

The 2026 framework outlines a tiered data set:

| Tier | Data type | Typical methods | |------|-----------|-----------------| | Tier 1 – Physicochemical characterisation | Particle size distribution (D10, D50, D90), zeta potential, crystallinity index, moisture content, residual lignin/hemicellulose | DLS, TEM, X‑ray diffraction (XRD), thermogravimetric analysis (TGA) | | Tier 2 – In‑vitro safety | Cytotoxicity (e.g., MTT assay), haemolysis, complement activation, oxidative stress (ROS generation) | Cell lines (HEK‑293, THP‑1), flow cytometry, ELISA for cytokines | | Tier 3 – In‑vivo toxicology (if required) | Sub‑chronic (28‑day) oral or intravenous study, local tolerance for injection sites, immunogenicity | Rodent models, histopathology, serum biochemistry | | Tier 4 – Stability and interaction | Compatibility with API, effect on dissolution, shelf‑life under ICH‑Q1A(R2) conditions | HPLC, DSC, accelerated stability (40 °C/75 % RH) |

Key quantitative thresholds include:

• Particle size: D50 ≤ 150 nm for oral excipients; ≤ 100 nm for parenteral.
• Zeta potential: |ζ| ≥ 30 mV to indicate colloidal stability.
• Residual lignin: ≤ 0.5 % w/w for pharmaceutical grade.

All analytical methods must be validated according to ICH Q2(R1) criteria (specificity, linearity, accuracy, precision). The FDA also expects a full Certificate of Analysis (CoA) and a Safety Data Sheet (SDS) for each batch used in clinical studies.

How does the framework align with existing REACH and ISO standards?

The FDA’s nanomaterial framework mirrors several international standards, facilitating global submissions:

• REACH (EU) requires registration of nanomaterials with a size‑distribution report and a nano‑specific safety assessment. The data elements (size, surface chemistry, toxicology) are largely identical to the FDA’s Tier 1‑3 requirements, allowing a single data package to satisfy both jurisdictions.
• ISO 22412 (Nanotechnologies – Vocabulary and definitions) and ISO 22416 (Nanomaterials – Safety information) provide terminology and risk‑assessment matrices that the FDA references in its guidance. Compliance with these ISO standards therefore reduces the risk of divergent expectations.
• USP <1079> (Nanomaterial Characterisation) and EP Chapter 3.2.3 (Nanomaterials) also prescribe similar analytical techniques. Aligning the analytical SOPs with USP and EP ensures that the data are acceptable to the FDA.

Manufacturers that already maintain REACH‑compliant dossiers for nanocellulose can repurpose much of that documentation for FDA submissions, provided they update the dossier to reflect the FDA’s specific exposure calculations and the required toxicology tier.

What timelines and compliance strategies should manufacturers consider?

Given the 2026 implementation date, a pragmatic timeline is:

1. 2024‑Q3 – Conduct a gap analysis against the draft guidance; identify missing characterisation data.
2. 2024‑Q4 to 2025‑Q2 – Generate Tier 1 data for all nanocellulose grades intended for use; validate analytical methods.
3. 2025‑Q3 – Perform Tier 2 in‑vitro safety assays; compile a preliminary safety dossier.
4. 2025‑Q4 – If the product is a novel parenteral formulation, initiate Tier 3 in‑vivo studies; otherwise, finalise the GRAS or IND submission package.
5. 2026‑Q1 – Submit the complete CMC section to the FDA; request a pre‑IND meeting to confirm data adequacy.
6. 2026‑Q2 onward – Address any FDA RFI; implement any required post‑approval monitoring (e.g., pharmacovigilance for nanocellulose‑related adverse events).

Key compliance strategies include:

• Early engagement: Request a Type C meeting with the FDA to discuss the nanocellulose data package before formal submission.
• Batch‑to‑batch consistency: Implement a robust quality‑by‑design (QbD) approach, monitoring critical quality attributes (CQAs) such as particle size and surface charge for each production run.
• Cross‑functional documentation: Align the CMC, toxicology, and regulatory affairs teams to ensure a single, coherent dossier.
• Leverage existing suppliers: Molekula, for example, provides nanocellulose with documented CoA and SDS, reducing the burden of raw‑material characterisation.

By following a staged approach and integrating international standards, manufacturers can meet the FDA’s expectations without significant delays.

Frequently asked

• What defines a nanomaterial under the FDA’s 2026 framework? A material is a nanomaterial if ≥ 50 % of its particles fall within the 1‑100 nm size range, as measured by validated techniques.

• Is a GRAS notification sufficient for nanocellulose used in tablets? It can be, provided the safety dossier demonstrates a history of safe use and meets the exposure and toxicology thresholds outlined in the guidance.

• Do I need in‑vivo studies for oral nanocellulose excipients? Generally not, if Tier 2 in‑vitro data show no cytotoxicity and the exposure estimate is below the threshold of concern; however, the FDA may still request a sub‑chronic study for novel grades.

• How can I align my US submission with REACH requirements? Use the same physicochemical and toxicology data sets, adapt the exposure calculations to US dosing scenarios, and ensure the dossier includes both FDA‑specific and REACH‑specific risk assessments.